Trading Update

Advanced Medical Solutions Grp PLC
18 December 2007


For Immediate Release                                           18 December 2007


                      Advanced Medical Solutions Group plc
                            ('AMS' or 'the Company')


                                 Trading Update


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, today announces an update on current trading prior
to its close period for the year to 31 December 2007. The Company's preliminary
results will be announced in March 2008.


Dr. Geoffrey Vernon, Chairman of Advanced Medical Solutions Group plc, stated:


'The business has continued to make excellent progress during the second half of
the year and I am pleased to report that the Group is trading at the top end of
market expectations for revenues, profitability and cash generation. The outlook
remains positive with the business continuing to perform well across key
products and geographies.'


                                     -ENDS-


For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer
Mary Tavener, Finance Director                    Tel: [phone]
www.admedsol.com

Buchanan Communications                           Tel: [phone]
Mark Court, Mary-Jane Johnson


Landsbanki Securities (UK) Ltd                    Tel: [phone]
Shaun Dobson / Xavier de Mol


Notes to Editors:


Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.


Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the
design, development and manufacture of innovative and technologically advanced
products for woundcare and other medical applications.


In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move a product from design and development through to production and delivery
ready for distribution into customer markets.


The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing topical wounds sold direct to hospitals or through
distributors.


AMS's technology and products currently serve the majority of the key global
markets and strategic partners.



                      This information is provided by RNS
            The company news service from the London Stock Exchange